IDH2 and osteosarcoma: The authors identified mutations in three out of 36 valid samples (8.3 %), with two patients (Patient 1 with chondrosarcoma and Patient 3 with osteosarcoma) having mutations in IDH2, and one patient with grade II conventional chondrosarcoma (Patient 2) having a mutation in TP53.